liraglutide

Overview

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) developed as an acylated analogue of the endogenous incretin hormone GLP-1. Originally approved for the management of type 2 diabetes mellitus (under the trade name Victoza) and subsequently for chronic weight management (Saxenda), liraglutide exerts its primary pharmacological effects by binding to and activating the GLP-1 receptor (GLP1R), a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and multiple peripheral tissues. Receptor activation stimulates cAMP production and downstream signaling through cAMP-dependent protein kinase catalytic subunits, leading to glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of food intake. Its fatty acid side chain confers a plasma half-life of approximately 13 hours, enabling once-daily subcutaneous administration. The molecule exists in a pH-dependent oligomeric equilibrium in solution, a biophysical property with implications for formulation stability and drug delivery.

Beyond its established metabolic indications, liraglutide has emerged as a pleiotropic therapeutic agent with demonstrated or investigated activity across neuropsychiatric, oncological, neurodegenerative, and organ-protective domains. Its structural similarity to other clinically deployed GLP-1RAs, including semaglutide and tirzepatide, has made it a key comparator in mechanistic studies probing the shared and divergent biological activities of this drug class. Active investigation of novel delivery systems, particularly oral formulations, reflects ongoing efforts to broaden accessibility and patient adherence beyond the injectable route.

Focus of Latest Publications

Recent publications on liraglutide have focused on diverse preclinical and translational questions, including neuropsychiatric effects, postoperative cognition, metabolic complications, peptide formulation, and potential anticancer activity. In a mouse depression model, liraglutide was reported to alleviate depressive-like behavior through a gut-brain pathway that was independent of GLP1R, with efficacy retained in GLP1R-antagonist-treated and GLP1R-/- mice but abolished by gut microbiota depletion. Multi-omics analyses implicated increased Lactobacillus delbrueckii and restoration of the endocannabinoid 2-arachidonoylglycerol, and fecal microbiota transplantation or bacterial colonization reproduced the antidepressant effect. Another study in aged mice found that liraglutide improved postoperative cognitive impairment after surgery and ischemia-reperfusion injury, associated with activation of the GLP-1R/NRF2 axis, reduced reactive oxygen species, suppression of NOD-like receptor pyrin domain-containing 3 inflammasome components, and microglia-dependent protection of synaptic structure and behavior.

Several studies examined liraglutide in disease models beyond the central nervous system. In a rat model of type 2 diabetes, liraglutide was investigated for protection against diabetic lung injury and skeletal muscle damage, with the abstract indicating modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. A population-based pharmacovigilance analysis of muscle atrophy reports in the FAERS database found lower reporting odds for liraglutide compared with all other drugs, although this was presented as signal detection rather than evidence of causality. In cancer cell studies, liraglutide was reported to exert antiproliferative effects in MCF7 breast and PC-3 prostate cancer cells, increasing GLP1R expression and cAMP/PKA signaling, inducing apoptosis and cell-cycle arrest, suppressing PI3K/AKT/mTOR and glycolytic regulators, upregulating PTEN and AMPKα, and altering adipokines, oxidative stress markers, and apoptosis-related proteins including B-cell lymphoma 2 and caspase-3.

Other recent work has addressed liraglutide as a peptide therapeutic and as a modulator of protein aggregation. An NMR study used liraglutide and semaglutide as model GLP-1 analogs to show that methyl proton spin relaxation rate ratios can sensitively detect pH-dependent oligomerization changes relevant to formulation development and stability control. In a separate biophysical study, liraglutide was among the FDA-approved GLP-1 receptor agonists shown to inhibit initiation of toxic Beta amyloid 42 aggregation; it strongly suppressed primary nucleation, modestly inhibited secondary nucleation, and produced fibrils with reduced maturity, increased tortuosity and length, and diminished self-replication capacity. These findings were discussed as providing molecular-level insight into possible anti-amyloid actions of GLP-1 receptor agonists.

Liraglutide has also been explored as an orally deliverable peptide drug. A virus-inspired mesoporous silica nanoparticle system functionalized with cell-penetrating peptide and hyaluronic acid was developed to encapsulate liraglutide, achieving high loading, pH-responsive release, enhanced intestinal uptake, and improved ex vivo permeability. In diabetic rats, oral liraglutide delivered by this platform lowered fasting blood glucose and body weight, with effects approaching those of subcutaneous administration. Together, these publications portray liraglutide as a therapy under active investigation not only for metabolic disease, but also for neurobehavioral, inflammatory, oncologic, and formulation-related applications.

Key Publications

NEWJun Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. (Cell host & microbe, 2026, PMID 42269582): "Here, we demonstrate that liraglutide alleviates depression through a gut-brain pathway that operates independently of GLP-1R."
May Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. (Molecular biology reports, 2026, PMID 42189284): "This study investigated the protective effects of liraglutide against pulmonary and muscular impairments in a rat model of type 2 diabetes."
Jun The GLP-1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC-3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and Adipokines. (Journal of biochemical and molecular toxicology, 2026, PMID 42152582): "This research explored the anticancer activities of the glucagon-like peptide-1 receptor agonist (GLP1Ra) liraglutide using MCF7 breast and PC-3 prostate cancer cell lines."
May Methyl Proton Spin Relaxation (R2/R1) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs. (Analytical chemistry, 2026, PMID 42131979): "Here, using glucagon-like peptide-1 (GLP-1) analogs liraglutide and semaglutide as model peptides, we introduce the methyl proton spin relaxation rate ratio (R2/R1) as a sensitive NMR metric for detecting pH-dependent changes in peptide oligomerization."
May Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. (Journal of the American Chemical Society, 2026, PMID 42133988): "Herein, we investigated five FDA-approved GLP-1RAs, and show semaglutide, tirzepatide, and liraglutide inhibit Aβ42 aggregation."
May Liraglutide alleviates postoperative cognitive impairment via NRF2/NLRP3 signal pathway in aged mice. (Neuroscience letters, 2026, PMID 42102962): "This study investigated whether the GLP-1R agonist liraglutide (LIR) could alleviate POCD in aged mice and explored the underlying mechanisms."
May Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study. (Clinical nutrition (Edinburgh, Scotland), 2026, PMID 41864088): "In contrast, exenatide (ROR = 0.26, 95 % CI = 0.12-0.55) and liraglutide (ROR = 0.27, 95 % CI = 0.09-0.83) were associated with significantly lower reporting odds."
May Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption. (Biomaterials advances, 2026, PMID 41604908): "To address these challenges, a novel virus-mimicking nanocarrier was developed for the oral delivery of liraglutide."